Key result
Natriuretic peptides and newer biomarkers such as midregional pro-adrenomedullin, ST2, and NGAL are emerging as useful tools in the diagnosis, prognosis, and management of heart failure.
This review highlights the established role of natriuretic peptides and the emerging utility of novel biomarkers like ST2 and NGAL in heart failure management.
May support biomarker-guided HF care; leaves open need for prospective validation before practice change.
Biomarkers can provide insights into underlying mechanisms and lead to better understanding of complex disease states. This enhanced understanding can then be integrated into disease management, which can lead to better therapies and ultimately to improved patient outcomes. The natriuretic peptides (NPs) are established cost-effective biomarkers in heart failure and have set the standard for how a well-validated biomarker can be useful in the diagnosis/prognosis, monitoring of response to therapy, and management of chronic disease. Newer biomarkers such as midregional pro-adrenomedullin, ST2, and neutrophil gelatinase-associated lipocalin are emerging as adjuncts to NPs in the management of heart failure patients.
No takes yet. Share an insight, caveat, or question.
Taub et al. (2010) conducted a review in Heart failure. Biomarkers (Natriuretic peptides, midregional pro-adrenomedullin, ST2, NGAL) was evaluated. Natriuretic peptides and newer biomarkers such as midregional pro-adrenomedullin, ST2, and NGAL are emerging as useful tools in the diagnosis, prognosis, and management of heart failure.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: